Showing results (271-280 of 389) with videos related to
Sort By:
Pageof 39
Future Oncology (London, England)|October 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Shoichi Kuyama, Nicolas Girard, et al.BMC Cancer|May 6, 2022
A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective studyKazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, et al.International Immunology|April 8, 2020
Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung diseaseKunihiro Suzuki, Toyoshi Yanagihara, Koichiro Matsumoto, et al.Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancerHibiki Udagawa, Hiroaki Akamatsu, Kentaro Tanaka, et al.Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)Minoru Fukuda, Takeshi Kitazaki, Daiki Ogawara, et al.Lung Cancer (Amsterdam, Netherlands)|October 31, 2016
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective studyKaname Nosaki, Miyako Satouchi, Takayasu Kurata, et al.European Journal of Cancer (Oxford, England : 1990)|July 3, 2022
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockadeKazuki Takada, Sebastiano Buti, Melissa Bersanelli, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?Takayasu Kurata, Keitaro Matsuo, Minoru Takada, et al.The Lancet. Oncology|September 2, 2014
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyTakashi Seto, Terufumi Kato, Makoto Nishio, et al.Cancer Management and Research|December 22, 2021
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, et al.Pageof 39